Trials / Active Not Recruiting
Active Not RecruitingNCT05039450
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 182 (actual)
- Sponsor
- Akero Therapeutics, Inc · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in cirrhotic subjects with biopsy-proven F4 compensated NASH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EFX | Investigational drug, Efruxifermin |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2021-07-30
- Primary completion
- 2023-08-25
- Completion
- 2025-05-01
- First posted
- 2021-09-09
- Last updated
- 2025-04-09
Locations
49 sites across 3 countries: United States, Mexico, Puerto Rico
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05039450. Inclusion in this directory is not an endorsement.